{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:36:39Z","timestamp":1783528599095,"version":"3.55.0"},"reference-count":51,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2010,7,27]],"date-time":"2010-07-27T00:00:00Z","timestamp":1280188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:p>\n                    <jats:bold>Aims:<\/jats:bold>\n                    To assess the efficacy and safety of ezetimibe\/simvastatin (\n                    <jats:italic>E\/S<\/jats:italic>\n                    ) plus extended\u2010release niacin (\n                    <jats:italic>N<\/jats:italic>\n                    ) in hyperlipidaemic patients with diabetes mellitus (DM), metabolic syndrome (MetS) without DM (MetS\/non\u2010DM) or neither (non\u2010DM\/non\u2010MetS).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    A subgroup analysis of a double\u2010blind, 64\u2010week trial of 1220 randomized patients who received\n                    <jats:italic>E\/S<\/jats:italic>\n                    (10\/20 mg) +\n                    <jats:italic>N<\/jats:italic>\n                    (to 2 g) or\n                    <jats:italic>E\/S<\/jats:italic>\n                    (10\/20 mg) for 64 weeks, or\n                    <jats:italic>N<\/jats:italic>\n                    (to 2 g) for 24 weeks then\n                    <jats:italic>E\/S<\/jats:italic>\n                    (10\/20 mg) +\n                    <jats:italic>N<\/jats:italic>\n                    (2 g) or\n                    <jats:italic>E\/S<\/jats:italic>\n                    (10\/20 mg) for 40 additional weeks. The evaluable populations of this analysis included n = 765 patients at 24 weeks and n = 574 at 64 weeks. Among those receiving\n                    <jats:italic>N<\/jats:italic>\n                    , only those who attained the 2\u2010g dose were included in the analysis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    <jats:italic>E\/S<\/jats:italic>\n                    +\n                    <jats:italic>N<\/jats:italic>\n                    improved levels of low\u2010density lipoprotein cholesterol, other lipids and lipoprotein ratios compared with\n                    <jats:italic>N<\/jats:italic>\n                    and\n                    <jats:italic>E\/S<\/jats:italic>\n                    at 24 weeks and\n                    <jats:italic>E\/S<\/jats:italic>\n                    at 64 weeks. The combination increased high\u2010density lipoprotein cholesterol and apolipoprotein AI comparably to\n                    <jats:italic>N<\/jats:italic>\n                    and more than\n                    <jats:italic>E\/S<\/jats:italic>\n                    .\n                    <jats:italic>E\/S<\/jats:italic>\n                    +\n                    <jats:italic>N<\/jats:italic>\n                    reduced high\u2010sensitivity C\u2010reactive protein (hsCRP) levels more effectively than\n                    <jats:italic>N<\/jats:italic>\n                    and similarly to\n                    <jats:italic>E\/S<\/jats:italic>\n                    .\n                    <jats:italic>E\/S<\/jats:italic>\n                    +\n                    <jats:italic>N<\/jats:italic>\n                    was generally well tolerated. Discontinuations due to flushing with\n                    <jats:italic>N<\/jats:italic>\n                    and\n                    <jats:italic>E\/S<\/jats:italic>\n                    +\n                    <jats:italic>N<\/jats:italic>\n                    were comparable and greater than\n                    <jats:italic>E\/S<\/jats:italic>\n                    in all subgroups. Fasting glucose trended higher for\n                    <jats:italic>N<\/jats:italic>\n                    vs.\n                    <jats:italic>E\/S.<\/jats:italic>\n                    Glucose elevations from baseline to 12 weeks were highest for patients with DM (24.9 mg\/dl for\n                    <jats:italic>N<\/jats:italic>\n                    , 21.2 mg\/dl for\n                    <jats:italic>E\/S<\/jats:italic>\n                    +\n                    <jats:italic>N<\/jats:italic>\n                    , 17.5 mg\/dl for\n                    <jats:italic>E\/S<\/jats:italic>\n                    ); fasting glucose then declined to pretreatment levels at 64 weeks in all subgroups. New\u2010onset DM was more frequent among MetS patients than those without MetS during the first 24 weeks and trended higher among those assigned to\n                    <jats:italic>N<\/jats:italic>\n                    \u2010containing regimens [n = 5(5.1%) for\n                    <jats:italic>N<\/jats:italic>\n                    , n = 2(1.7%) for\n                    <jats:italic>E\/S<\/jats:italic>\n                    , n = 21(8.8%) for\n                    <jats:italic>E\/S<\/jats:italic>\n                    +\n                    <jats:italic>N<\/jats:italic>\n                    ]; during 24\u201364 weeks, diabetes was diagnosed in five additional patients in the\n                    <jats:italic>E\/S<\/jats:italic>\n                    (cumulative incidence of 5.9%) and one in the\n                    <jats:italic>E\/S<\/jats:italic>\n                    +\n                    <jats:italic>N<\/jats:italic>\n                    (cumulative incidence of 9.2%) groups. Treatment\u2010incident elevations in uric acid levels were increased among subjects assigned to\n                    <jats:italic>N<\/jats:italic>\n                    \u2010containing regimens, but there were no effects on symptomatic gout.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Combination\n                    <jats:italic>E\/S<\/jats:italic>\n                    +\n                    <jats:italic>N<\/jats:italic>\n                    is a safe treatment option for hyperlipidaemic patients including those with DM and MetS, but requires monitoring of glucose and potentially uric acid levels.\n                  <\/jats:p>","DOI":"10.1111\/j.1463-1326.2010.01289.x","type":"journal-article","created":{"date-parts":[[2010,7,27]],"date-time":"2010-07-27T13:54:04Z","timestamp":1280238844000},"page":"983-993","source":"Crossref","is-referenced-by-count":16,"title":["Long\u2010term efficacy and safety of ezetimibe\/simvastatin coadministered with extended\u2010release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome"],"prefix":"10.1111","volume":"12","author":[{"given":"S.","family":"Fazio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R.","family":"Guyton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. E.","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Tershakovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,27]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.169404"},{"key":"e_1_2_7_3_2","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.","volume":"113","author":"Smith SC","year":"2006","journal-title":"Circulation"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000133317.49796.0E"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9018"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e3282364add"},{"key":"e_1_2_7_7_2","unstructured":"Niaspan [product insert]2007. Abbott Laboratories North Chicago IL."},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011090"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199011083231901"},{"key":"e_1_2_7_10_2","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.","volume":"264","author":"Kane JP","year":"1990","journal-title":"JAMA"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1988.tb15891.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-2-200501180-00008"},{"key":"e_1_2_7_13_2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease.","volume":"231","author":"Coronary Drug Project Research Group.","year":"1975","journal-title":"JAMA"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.11.018"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1263"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.14.1568"},{"key":"e_1_2_7_17_2","unstructured":"Vytorin [product insert]2008. Merck\/Schering\u2010Plough Pharmaceuticals North Wales PA."},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.11.016"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.11.023"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X132721"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.05.003"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.12.1579"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2008.02.002"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.3132\/dvdr.2006.020"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/met.2006.0033"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X2321"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.03.003"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.10.001"},{"issue":"1","key":"e_1_2_7_29_2","first-page":"A191.","article-title":"New onset diabetes mellitus among patients with type IIa\/IIb hyperlipidemia (HL) taking ezetimibe\/ simvastatin (E\/S) +\/\u2010 niacin (N) in a randomized trial","volume":"58","author":"Guyton JR","year":"2009","journal-title":"Diabetes"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.08.070"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.09.013"},{"key":"e_1_2_7_32_2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1177\/106002809703100602","article-title":"Combination of low\u2010dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control.","volume":"31","author":"Gardner SF","year":"1997","journal-title":"Ann Pharmacother J"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/14746514040040020301"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00847-9"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01597.x"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2006.06.028"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.01.073"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2007.06.022"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000080897.52664.94"},{"key":"e_1_2_7_40_2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1161\/01.CIR.0000136581.59584.0E","article-title":"C\u2010reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study.","volume":"110","author":"Rutter MK","year":"2004","journal-title":"Circulation"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-S013"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2003.10.009"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13636-7"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12948-0"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.3.357"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.10.2713"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61965-6"},{"key":"e_1_2_7_49_2","unstructured":"University of Oxford.2007.Treatment of HDL to reduce the incidence of vascular events HPS2\u2010THRIVE.Available from URL:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00461630. Accessed 21 August 2009."},{"key":"e_1_2_7_50_2","unstructured":"National Heart Lung and Blood Institute (NHLBI).2005.AIM HIGH: niacin plus statin to prevent vascular events.Available from URL:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00120289. Accessed 12 August 2009."},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.10.031"},{"key":"e_1_2_7_52_2","first-page":"1678","volume-title":"JAMA","author":"Howard BV","year":"2008"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2010.01289.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2010.01289.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:36:53Z","timestamp":1761885413000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2010.01289.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,27]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1111\/j.1463-1326.2010.01289.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01289.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,27]]}}}